secwatch.observer — SEC 8-K summary
======================================

Issuer:     AVENUE THERAPEUTICS, INC. (ATXI)
CIK:        0001644963
Form:       8-K
Filed at:   2025-03-07T23:59:59+00:00
Accession:  0001437749-25-006685
Event type: other_material
Sentiment:  negative
Materiality: 0.80
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Nasdaq grants Avenue Therapeutics continued listing exception; AnnJi seeks to terminate AJ201 license
--------------------------------------------------------------------------------

- Nasdaq Panel granted continued listing subject to: public disclosure by Mar 14, fundraising update by Mar 14, AJ201 trial results by Apr 15.
- AnnJi sent termination notice alleging material breaches of AJ201 license; Avenue believes claims are meritless and will contest.
- Avenue filed emergency arbitration to block AnnJi from unblinding clinical data in a way that would exhaust irreplaceable samples.
- Company must still regain compliance with stockholders' equity requirement; no assurance of success.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1644963/000143774925006685/0001437749-25-006685-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1644963/000143774925006685/atxi20250307_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-25-006685

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer